Related Experiment Video
Updated: Feb 13, 2026
09:16
Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Published on: May 5, 2022
3.1K
Durvalumab in urothelial cancers
Pernelle Lavaud1, Zineb Hamilou1, Yohann Loriot1
1a Gustave Roussy, Department de Medicine Oncologique & INSERM U981 , Université Paris-Saclay , Villejuif , France.
Expert Review of Anticancer Therapy
|March 1, 2018
Summary
Durvalumab shows significant and lasting responses in advanced urothelial carcinoma, offering a new treatment option. Further research is needed to identify biomarkers for immune-oncology agents in bladder cancer.
Area of Science:
- Uro-oncology
- Medical oncology
- Immunotherapy
Background:
- Urothelial bladder cancer presents a poor prognosis at advanced stages, with limited effective therapies beyond cisplatin-based chemotherapy.
- Current first-line and second-line treatments for advanced urothelial carcinoma have significant limitations, including patient ineligibility and minimal activity.
- Immune-checkpoint inhibitors represent a paradigm shift in bladder cancer treatment, necessitating updated therapeutic strategies.
Purpose of the Study:
- To review the development of durvalumab for urothelial carcinoma.
- To provide an overview of durvalumab's safety, activity, efficacy, and future potential in advanced bladder cancer.
Main Methods:
- Review of clinical data and published literature on durvalumab in urothelial carcinoma.
- Analysis of safety profiles, response rates, and durability of response.
- Exploration of future therapeutic perspectives and combination strategies.
Main Results:
- Durvalumab is a well-tolerated agent.
- Durvalumab demonstrates major and durable responses in patients with advanced urothelial carcinoma.
- Immune-oncology agents are reshaping the treatment landscape for bladder cancer.
Conclusions:
- Durvalumab offers a promising therapeutic option for advanced urothelial carcinoma.
- Combination therapies involving durvalumab are anticipated to be effective treatment strategies.
- Identification of predictive biomarkers for response to immune-oncology agents is crucial for optimizing treatment.
More Related Videos
Related Concept Videos
02:18Cancer
54.6K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.6K
02:12What is Cancer?
14.5K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.5K
02:59Cancer Prevention
8.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
8.2K
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
01:30Cancer Vaccines
1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
01:30Skin Cancer
6.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.0K